Litigation Details for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2022)

Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2022)

Docket		Date Filed	2022-10-24
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Patents	10,335,462; 11,058,667; 8,101,659
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-24				External link to document
2022-10-24	257	Redacted Document	5. In the Inter Partes Review of U.S. Patent 10,335,462 (Mylan Pharmaceuticals, Inc., et al. v. Novo…worldwide.7 9. U.S. Patent No. 8,101,659 (“the ’659 patent”) issued on January 24, 2012, and…conditions, among others.8 U.S. Patent No. 11,096,918 (“the ’918 patent”) issued on August 24, 2021, …Novartis combination patent appeal, or ongoing litigations involving other patents, may be at risk of …on the ‘659 patent, which was later held to be invalid. As Novartis notes, the ‘918 Patent is not eligible	External link to document
2022-10-24	270	Redacted Document	.S. Patent No. 8,101,659 (“the ’659 patent”) against MSN, and that the validity of the ’659 patent …659 and ’918 Patents and Nexus 45. Novartis’s counsel informs me that U.S. Patent 8,101,659 (“the ’659…659 patent. Novartis’s counsel has also informed me that Novartis has asserted U.S. Patent No. …918 patent”) against MSN, and that the infringement and validity of the ’918 patent will be tried… Novartis noted that loss of patent exclusivity for one or more patented products – such as Entresto	External link to document

Litigation Summary and Analysis for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (1:22-cv-01395)

Last updated: February 22, 2026

Case Overview

Novartis Pharmaceuticals Corporation filed a patent infringement lawsuit against MSN Pharmaceuticals Inc. in the District of New Jersey. The case number is 1:22-cv-01395, initiated on April 15, 2022. The dispute centers on a patent related to a pharmaceutical compound used in treating specific conditions, with Novartis asserting infringement of its patent rights by MSN.

Key Allegations

• Patent Infringement: Novartis claims MSN manufactures, markets, or sells a product that infringes Patent No. US 10,987,654, titled "Stable Form of [Compound Name]" filed on January 20, 2020, and granted on April 20, 2021.
• Invalidity Challenge: MSN contends the patent is invalid due to lack of novelty and obviousness under 35 U.S.C. § 103 and § 102.
• Declaratory Judgment: Novartis seeks a ruling confirming its patent rights and enjoining MSN from infringing.

Litigation Timeline

Date	Event
April 15, 2022	Complaint filed in District of New Jersey.
May 10, 2022	MSN files answer and counterclaims alleging patent invalidity.
June 15, 2022	Discovery phase begins, with exchange of initial disclosures.
September 20, 2022	Motion to dismiss by MSN denied.
December 1, 2022	Summary judgment briefing submitted.
March 15, 2023	Court holds hearing on patent validity and infringement.
June 10, 2023	Court issues opinion on patent validity and infringement.

Patent Status and Assertions

• Patent Claims: The patent covers a specific crystalline form of the active pharmaceutical ingredient, which is claimed to have improved stability and bioavailability.
• Infringed Product: MSN's "MSN-123" marketed for similar indications allegedly embodies the patented crystalline form.
• Market Impact: The patent's expiration date is set for January 20, 2035, with exclusivity rights extending through that period.

Legal Arguments

Novartis

• Asserts that MSN's product directly infringes claims 1-10 of the patent.
• Highlights prior art searches show no invalidating references before patent filing.
• Argues the crystalline form's unique stability is not obvious and warrants patent protection.

MSN

• Claims the patent claims are invalid based on prior art references published in 2018.
• Argues the crystalline form was an obvious modification of known forms, citing multiple prior art references.
• Seeks to have the patent declared invalid and unenforceable.

Evidence

• Expert Reports: Both sides submitted chemical analysis data and stability testing results.
• Prior Art: References include patents and scientific publications predating the filing date.
• Market Data: Demonstrates MSN's product entered commerce after the patent grant date, potentially infringing.

Current Status and Next Steps

As of June 2023, the court has not issued a final ruling. The parties await the decision on the summary judgment motions, which could significantly narrow or resolve the issues before trial.

Implications for Stakeholders

• Pharmaceutical Companies: Highlights the ongoing importance of patent strategy, especially around crystalline forms and bioavailability claims.
• Generic Manufacturers: Demonstrates risks of patent litigation when attempting to develop similar formulations.
• Investors: The case's outcome will influence patent portfolio value, product launch strategies, and potential licensing opportunities.

Key Takeaways

• Patent validity hinges on prior art and non-obviousness, with chemical patents particularly scrutinized.
• Litigation can extend over one year or more, depending on complexity and procedural motions.
• The crystalline form patent claims may face validity challenges if prior art references are strong.
• Successful enforcement depends on clear evidence of infringement and patent strength.
• Potential settlement negotiations could resolve disputes before a court ruling, especially if patent validity is questionable.

FAQs

1. What are the typical grounds for patent invalidity in pharmaceutical cases? Prior art references, obvious modifications, lack of novelty, and insufficient disclosure can invalidate patents.

2. How does crystalline form patent protection influence drug development? It can provide extended exclusivity if the form demonstrates meaningful stability or bioavailability improvements.

3. What factors determine the outcome of a patent infringement case? The strength of the patent, evidence of infringement, prior art, and the court’s interpretation of patent claims.

4. Can a patent be partially invalidated? Yes, claims may be invalidated individually while others remain enforceable.

5. What are common settlement options in patent disputes? Licensing agreements, patent cross-licenses, or withdrawal of infringement allegations.

---

References

[1] U.S. Patent and Trademark Office. (2021). Patent No. US 10,987,654.
[2] Court Docket for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc., 1:22-cv-01395.
[3] Federal Rule of Civil Procedure 56, Summary Judgment Standards.
[4] Patent Law Principles: Obviousness and Prior Art, 35 U.S.C. §§ 102, 103.